Nuvectis Pharma, Inc. (NVCT) NASDAQ
9.51
-0.24(-2.46%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
9.51
-0.24(-2.46%)
Currency In USD
| Previous Close | 9.75 |
| Open | 9.53 |
| Day High | 9.72 |
| Day Low | 9.47 |
| 52-Week High | 13.34 |
| 52-Week Low | 5.55 |
| Volume | 69,396 |
| Average Volume | 79,211 |
| Market Cap | 252.26M |
| PE | -7.26 |
| EPS | -1.31 |
| Moving Average 50 Days | 9.16 |
| Moving Average 200 Days | 7.72 |
| Change | -0.24 |
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
GlobeNewswire Inc.
Feb 11, 2026 12:30 PM GMT
FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serio
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
GlobeNewswire Inc.
Dec 17, 2025 12:00 PM GMT
The study is designed to evaluate the safety and clinical activity of NXP900 in combination with osimertinib in patients with epidermal growth factor receptor mutated (EGFR mut+) non-small cell lung cancer (NSCLC) whose cancers initially responded to
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
GlobeNewswire Inc.
Nov 25, 2025 1:00 PM GMT
Event scheduled for Tuesday, December 2nd at 8:00 AM ETFort Lee, NJ, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT, the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precisio